A Phase II Investigation of Vorinostat in Combination With Intravenous Fludarabine, Mitoxantrone, and Dexamethasone in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Trial Profile

A Phase II Investigation of Vorinostat in Combination With Intravenous Fludarabine, Mitoxantrone, and Dexamethasone in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2016

At a glance

  • Drugs Vorinostat (Primary) ; Dexamethasone; Dexamethasone; Fludarabine; Mitoxantrone
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms ZOLINZA
  • Most Recent Events

    • 13 Apr 2016 Status changed from not yet recruiting to discontinued because they had collected data of a total of 19 patients for an interim analysis, but there are less than 7 responses out of the initial 19 patients
    • 02 Jan 2013 Planned initiation date changed from 1 Apr 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 23 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top